To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
TPG scores exit with $1.2bn Bayer deal
The sale of vitamin maker Schiff is expected to produce a healthy return for TPG's growth arm, which helped to bring in a new management team and led two add-on acquisitions.
